Synthesis and preclinical testing of a selective beta-subtype agonist of thyroid hormone receptor ZTA-261
Masakazu Nambo,Taeko Nishiwaki-Ohkawa,Akihiro Ito,Zachary T Ariki,Yuka Ito,Yuuki Kato,Muhammad Yar,Jacky C-H Yim,Emily Kim,Elizabeth Sharkey,Keiko Kano,Emi Mishiro-Sato,Kosuke Okimura,Michiyo Maruyama,Wataru Ota,Yuko Furukawa,Tomoya Nakayama,Misato Kobayashi,Fumihiko Horio,Ayato Sato,Cathleen M Crudden,Takashi Yoshimura
DOI: https://doi.org/10.1038/s43856-024-00574-z
2024-08-06
Abstract:Background: Thyroid hormones (TH) regulate the basal metabolic rate through their receptors THRα and THRβ. TH activates lipid metabolism via THRβ, however, an excess amount of TH can lead to tachycardia, bone loss, and muscle wasting through THRα. In recent years, TH analogs that selectively bind to THRβ have gained attention as new agents for treating dyslipidemia and obesity, which continue to pose major challenges to public health worldwide. Methods: We developed a TH analog, ZTA-261, by modifying the existing THRβ-selective agonists GC-1 and GC-24. To determine the THRβ-selectivity of ZTA-261, an in vitro radiolabeled TH displacement assay was conducted. ZTA-261 was intraperitoneally injected into a mouse model of high-fat diet-induced obesity, and its effectiveness in reducing body weight and visceral fat, and improving lipid metabolism was assessed. In addition, its toxicity in the liver, heart, and bone was evaluated. Results: ZTA-261 is more selective towards THRβ than GC-1. Although ZTA-261 is less effective in reducing body weight and visceral fat than GC-1, it is as effective as GC-1 in reducing the levels of serum and liver lipids. These effects are mediated by the same pathway as that of T3, a natural TH, as evidenced by similar changes in the expression of TH-induced and lipid metabolism-related genes. The bone, cardiac, and hepatotoxicity of ZTA-261 are significantly lower than those of GC-1. Conclusions: ZTA-261, a highly selective and less toxic THRβ agonist, has the potential to be used as a drug for treating diseases related to lipid metabolism.